SEC Filing | OptimizeRx Corporation

View:

Download DOC

Download PDF

Download XLS

Download XBRL

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

FORM 10-Q

☒ Quarterly Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

For the quarterly period ended June 30, 2018

☐ Transition Report pursuant to 13 or 15(d) of the Securities Exchange Act of 1934

For the transition period from __________ to __________

Commission File Number: 000-53605

OptimizeRx Corporation

(Exact name of registrant as specified in its charter)

Nevada		26-1265381
(State or other jurisdiction of incorporation or organization)		(IRS Employer Identification No.)
400 Water Street, Suite 200 Rochester, MI, 48307
(Address of principal executive offices)

248-651-6568

(Registrant’s telephone number)

_______________________________________________________________

(Former name, former address and former fiscal year, if changed since last report)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days Yes ☒ ☐ No

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§ 229.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company.

☐ Large accelerated filer	☐ Accelerated filer
☐ Non-accelerated filer	☒ Smaller reporting company
	☐ Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

State the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date: 11,637,546 common shares as of July 31, 2018.

TABLE OF CONTENTS
		Page

PART I – FINANCIAL INFORMATION

Item 1:	Financial Statements	F-1
Item 2:	Management’s Discussion and Analysis of Financial Condition and Results of Operations	2
Item 3:	Quantitative and Qualitative Disclosures About Market Risk	6
Item 4:	Controls and Procedures	6

PART II – OTHER INFORMATION

Item 1:	Legal Proceedings	7
Item 1A:	Risk Factors	7
Item 2:	Unregistered Sales of Equity Securities and Use of Proceeds	7
Item 3:	Defaults Upon Senior Securities	7
Item 4:	Mine Safety Disclosure	7
Item 5:	Other Information	7
Item 6:	Exhibits	8

PART I - FINANCIAL INFORMATION

Item 1. Financial Statements

Our consolidated financial statements included in this Form 10-Q are as follows:

F-1	Condensed Consolidated Balance Sheets as of June 30, 2018 (unaudited) and December 31, 2017;
F-2	Condensed Consolidated Statements of Operations for the three and six months ended June 30, 2018 and 2017 (unaudited);
F-3	Condensed Consolidated Statements of Cash Flow for the six months ended June 30, 2018 and 2017 (unaudited);
F-4	Notes to Condensed Consolidated Financial Statements.

These consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America for interim financial information and the SEC instructions to Form 10-Q. In the opinion of management, all adjustments considered necessary for a fair presentation have been included. Operating results for the interim period ended June 30, 2018 are not necessarily indicative of the results that can be expected for the full year.

F-1

OPTIMIZERx CORPORATION

CONDENSED CONSOLIDATED BALANCE SHEETS

AS OF JUNE 30, 2018 AND DECEMBER 31, 2017

	June 30, 2018 (unaudited)			December 31, 2017
ASSETS
Current Assets
Cash and cash equivalents	$	12,003,864		$	5,122,573
Accounts receivable		2,954,782			2,257,276
Accounts receivable – related party		2,555,931			1,173,614
Prepaid expenses		215,108			255,428
Total Current Assets		17,729,685			8,808,891
Property and equipment, net		152,898			167,305
Other Assets
Patent rights, net		604,820			638,766
Web development and other intangible costs, net		152,381			143,730
Security deposit		5,049			5,049
Total Other Assets		762,250			787,545
TOTAL ASSETS	$	18,644,833		$	9,763,741

LIABILITIES AND STOCKHOLDERS’ EQUITY
Current Liabilities
Accounts payable – trade	$	176,940		$	457,289
Accrued expenses		828,540			953,947
Revenue share payable		994,142			1,177,136
Revenue share payable – related party		-			447,670
Deferred revenue		845,153			507,160
Total Liabilities		2,844,775			3,543,202
Stockholders’ Equity
Preferred stock, $0.001 par value, 10,000,000 shares authorized, no issued and outstanding at June 30, 2018 or December 31, 2017		-			-
Common stock, $0.001 par value, 166,666,667 shares authorized, 11,556,858 and 9,772,694 shares issued and outstanding at June 30, 2018 and December 31, 2017, respectively		11,557			9,773
Stock warrants		1,286,424			1,286,424
Additional paid-in-capital		44,915,896			35,287,464
Accumulated deficit		(30,413,819	)		(30,363,122	)
Total Stockholders’ Equity		15,800,058			6,220,539
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY	$	18,644,833		$	9,763,741

The accompanying notes are an integral part of these financial statements.

F-2

OPTIMIZERx CORPORATION

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED)

FOR THE THREE AND SIX MONTHS ENDED JUNE 30, 2018 AND 2017

	For the Three Months Ended					For the Six Months Ended
	June 30					June 30
	2018		2017			2018		2017
NET REVENUE
Revenue	$	3,192,138	$	2,252,222		$	5,961,257	$	3,652,540
Revenue – Related Party		1,907,336		613,601			3,250,453		1,365,356
TOTAL NET REVENUE		5,099,474		2,865,823			9,211,710		5,017,896
REVENUE SHARE EXPENSE		2,236,751		1,605,534			4,244,842		2,987,267
GROSS MARGIN		2,862,723		1,260,289			4,966,868		2,030,629
OPERATING EXPENSES		2,589,126		1,630,853			4,884,467		3,291,631
INCOME (LOSS) FROM OPERATIONS		273,597		(370,564	)		82,401		(1,261,002	)

OTHER INCOME (EXPENSE)
Interest income		6,912		9,063			8,929		16,819
Interest expense		-		-			-		-

TOTAL OTHER INCOME (EXPENSE)		6,912		9,063			8,929		16,819

INCOME (LOSS) BEFORE PROVISION FOR INCOME TAXES		280,509		(361,501	)		91,330		(1,244,183	)

PROVISION FOR INCOME TAXES		-		-			-		-
NET INCOME (LOSS)	$	280,509	$	(361,501	)	$	91,330	$	(1,244,183	)

WEIGHTED AVERGE NUMBER OF SHARES OUTSTANDING
BASIC		10,979,086		9,861,257			10,373,326		9,883,648
DILUTED		11,949,593		9,861,257			11,517,604		9,883,648

NET INCOME (LOSS) PER SHARE
BASIC	$	0.03	$	(0.04	)	$	0.01	$	(0.13	)
DILUTED	$	0.02	$	(0.04	)	$	0.01	$	(0.13	)

The accompanying notes are an integral part of these financial statements.

F-3

OPTIMIZERx CORPORATION

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)

FOR THE SIX MONTHS ENDED JUNE 30, 2018 AND 2017

	For the six months Ended June 30
	2018			2017
CASH FLOWS FROM OPERATING ACTIVITIES:
Net income (loss) for the period	$	91,330		$	(1,244,183	)
Adjustments to reconcile net income(loss) to net cash used in operating activities:
Depreciation and amortization		108,946			141,945
Stock and options issued for services		1,013,822			291,874
Changes in:
Accounts receivable		(2,079,823	)		638,602
Prepaid expenses		40,320			(866,333	)
Accounts payable		(280,349	)		534,743
Revenue share payable		(183,664	)		(751,094	)
Accrued expenses		(125,407	)		(91,981	)
Deferred revenue		195,966			650,331
NET CASH USED IN OPERATING ACTIVITIES		(1,218,859	)		(696,096	)

CASH FLOWS FROM INVESTING ACTIVITIES:
Purchase of property and equipment		(12,593	)		(24,599	)
Web development and other intangible costs		(56,651	)		(81,350	)
NET CASH USED IN INVESTING ACTIVITIES		(69,244	)		(105,949	)

CASH FLOWS FROM FINANCING ACTIVITIES:
Net proceeds from issuance of common stock for cash		8,169,394			-
Repurchase of common stock and stock payable		-			(390,000	)
NET CASH PROVIDED BY (USED IN) FINANCING ACTIVITIES		8,169,394			(390,000	)
NET CHANGEIN CASH AND CASH EQUIVALENTS		6,881,291			(1,192,045	)
CASH AND CASH EQUIVALENTS - BEGINNING OF PERIOD		5,122,573			7,034,647
CASH AND CASH EQUIVALENTS - END OF PERIOD	$	12,003,864		$	5,842,602

SUPPLEMENTAL CASH FLOW INFORMATION:
Cash paid for interest	$	-		$	-
Cash paid for income taxes	$	-		$	-
Non-cash issuance of shares to WPP	$	447,000		$	-

The accompanying notes are an integral part of these financial statements.

F-4

OPTIMIZERx CORPORATION

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

JUNE 30, 2018

NOTE 1 – NATURE OF BUSINESS AND BASIS OF PRESENTATION

We are a leading provider of digital health messaging via electronic health records (EHRs), providing a direct channel for pharmaceutical companies to communicate with healthcare providers. Our cloud-based solution supports patient adherence to medications by providing real-time access to financial assistance, prior authorization, education and critical clinical information. Our network is comprised of leading EHR platforms and provides more than half the ambulatory healthcare providers access to these benefits within their workflow at the point of care.

The consolidated financial statements for the three and six months ended June 30, 2018 and 2017, have been prepared by us without audit pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”). In the opinion of management, all adjustments necessary to present fairly our financial position, results of operations, and cash flows as of June 30, 2018 and 2017, and for the periods then ended, have been made. Those adjustments consist of normal and recurring adjustments. The consolidated balance sheet as of December 31, 2017, has been derived from the audited consolidated balance sheet as of that date.

Certain information and note disclosures normally included in our annual financial statements prepared in accordance with generally accepted accounting principles have been condensed or omitted. These consolidated financial statements should be read in conjunction with a reading of the financial statements and notes thereto included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2017, as filed with the SEC.

The results of operations for the three and six months ended June 30, 2018, are not necessarily indicative of the results to be expected for the full year. Certain reclassifications have been made in our consolidated financial statements for the prior periods to conform to the presentation of our consolidated financial statements for the current periods.

NOTE 2 – NEW FINANCIAL ACCOUNTING STANDARDS

On January 1, 2018, we adopted the new accounting standard ASC 606, Revenue from Contracts with Customers, and all of the related amendments (“new revenue standard”). We recorded the change, which was immaterial, related to adopting the new revenue standard using the modified retrospective method. Under this method, we recognized the cumulative effect of initially applying the new revenue standard as an adjustment to the opening balance of retained earnings. This results in no restatement of prior periods, which continue to be reported under the accounting standards in effect for those periods. We expect the impact of the adoption of the new revenue standard to continue to be immaterial on an ongoing basis.

We have applied the new revenue standard to all contracts as of the date of initial application. The overwhelming majority of our revenue continues to be recognized when transactions occur, such as the delivery of a message. We previously recognized revenue related to set-ups when a program launched, and all related activities had been accomplished. Under the new revenue standard, we are recognizing revenue related to these set ups over the term of the initial contract. Since set up fees are generally small relative to the size of the overall contract and because most contracts are for a year or less, the impact of this change is immaterial.

The impact of recording this change as of January 1, 2018 resulted in an increase in deferred revenue of $142,027 at that date and a corresponding decrease in retained earnings as well. The impact of adopting the new revenue standard in 2018 resulted in lower revenues in the six months ended June 30, 2018. Had the new revenue standard not taken effect, our revenues for the period would have been higher by $144,262 and deferred revenues lower by $144,262. Almost all of these revenues are expected to be recognized by December 31, 2018, so the primary effect of the new revenue standard is to shift revenues between quarters by immaterial amounts. The impact of adopting the new revenue standard in 2018 also resulted in lower revenues in the three months ended June 30, 2018. Had the new revenue standard not taken effect, our revenues for the period would have been higher by $26,351.

F-5

OPTIMIZERx CORPORATION

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

JUNE 30, 2018

NOTE 3 – STOCKHOLDERS’ EQUITY

Effective May 14, 2018, in connection with our listing on the Nasdaq Capital Markets Exchange, we implemented a reverse split of our common stock by exchanging each three shares of our common stock for one share. The effect of this reverse split is presented in the accompanying financial statements as if it had been effective as off the beginning of the earliest period presented. We elected to round fractional shares up to the nearest whole number rather than redeem them for cash, and as a result we issued 908 additional shares.

Our Director Compensation Plan calls for issuance of 2,084 shares per quarter to each independent director. In 2018, we issued 6,252 shares valued at $28,875 and 8,336 shares valued at $89,945 for the quarters ended March 31, and June 30, respectively. In 2017, we issued 6,252 shares in each of the quarters ended March 31, 2017 and June 30, 2017, valued at $15,375 and $19,312, respectively.

In the quarter ended March 31, 2018, we issued 100,000 shares of common stock to a subsidiary of WPP, one of the world’s largest media companies, and a shareholder, in full payment of all amounts due under a comarketing agreement that covered certain WPP agencies, whereby we shared a portion of our revenue with those agencies related to programs awarded to us by those agencies. The shares were valued at $447,000, the market value of the stock on the date of issuance. The amount due was recorded as a liability in revenue share payable at December 31, 2017.

During the quarter ended June 30, 2018, in a private transaction, we issued 1,666,669 shares of our common stock for gross proceeds of $9,000,000. In connection with this transaction, we incurred equity issuance costs of $835,526 related to payments to advisors and legal fees associated with the transaction, resulting in net proceeds to the Company of $8,164,474.

We also issued 2,002 common shares and received proceeds of $4,920 in connection with the exercise of options by a former employee during the quarter ended June 30, 2018.

NOTE 4 – SHARE BASED PAYMENTS – OPTIONS AND STOCK AWARDS

We use the fair value method to account for stock-based compensation. We recorded $712,998 and $257,187 in compensation expense in the six months ended June 30, 2018 and 2017, respectively, related to options issued under our stock-based incentive compensation plan. This includes expense related to options issued in prior years for which the requisite service period for those options includes the current year, options granted in the current year and options repriced in the current year. The assumptions used in this model were similar to the assumptions set forth in our Annual Report on Form 10-K for the fiscal year ended December 31, 2017 related to grants in 2017. As also discussed in the 10-K, we increased the shares of common stock authorized under our stock option plan during the quarter to 1,833,333 million shares.

We also granted 130,000 shares of performance based stock awards during the six months ended June 30, 2018. These shares were valued at their fair market value of $4.20 per share on the date of grant. The grants are currently expected to vest. A total of $182,004 of expense has been recorded related to these grants.

NOTE 5 – COMMITMENTS AND CONTINGENCIES

Litigation

The company is not involved in any legal proceedings.

F-6

OPTIMIZERx CORPORATION

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

JUNE 30, 2018

NOTE 6 – RELATED PARTY TRANSACTIONS

WPP, a large international media conglomerate, owns approximately 18% of our common shares. As described in more detail in Note 3, Stockholders Equity, we issued 100,000 shares of our common stock to a subsidiary of WPP related to the finalization and termination of a co-marketing agreement.

Our customers are primarily pharmaceutical companies; however, sometimes their messaging programs are billed through media agencies. Revenues earned on messaging programs billed through media agencies owned by WPP are reflected as related party revenues on our income statement. Amounts due from those same agencies are reflected as related party accounts receivable on the balance sheet since their parent company owns a minority portion of our common shares.

NOTE 7 – NET INCOME (LOSS) PER SHARE

The following tables sets forth the computation of basic and diluted net income per share.

	Three months ended June 30					Six Months ended June 30
	2018		2017			2018		2017
Numerator
Net income loss	$	280,509	$	(361,501	)	$	91,330	$	(1,244,183	)

Denominator
Weighted average shares outstanding used in computing net income (loss) per share
Basic		10,979,086		9,861,257			10,373,326		9,883,648
Effect of dilutive stock options, warrants, and stock grants		970,507		-			1,144,278		-
Diluted		11,949,593		9,861,257			11,517,604		9,883,648

Net Income (Loss) per share
Basic	$	0.03	$	(0.04	)	$	0.01	$	(0.13	)
Diluted	$	0.02	$	(0.04	)	$	0.01	$	(0.13	)

NOTE 8 – SUBSEQUENT EVENTS

In July 2018, we issued 34,656 shares of common stock and received proceeds of $104,581 in connection with the exercise of options by former consultants and a former employee. In addition, in July 2018, we issued 46,032 shares of our common stock in connection with the cashless exercise of 70,842 warrants that were issued in March 2014 and would have otherwise expired in March 2019.

F-7

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

Forward-Looking Statements

Certain statements, other than purely historical information, including estimates, projections, statements relating to our business plans, objectives, and expected operating results, and the assumptions upon which those statements are based, are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements generally are identified by the words “believes,” “project,” “expects,” “anticipates,” “estimates,” “intends,” “strategy,” “plan,” “may,” “will,” “would,” “will be,” “will continue,” “will likely result,” and similar expressions. We intend such forward-looking statements to be covered by the safe-harbor provisions for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995, and are including this statement for purposes of complying with those safe-harbor provisions. Forward-looking statements are based on current expectations and assumptions that are subject to risks and uncertainties which may cause actual results to differ materially from the forward-looking statements. Our ability to predict results or the actual effect of future plans or strategies is inherently uncertain. Factors which could have a material adverse effect on our operations and future prospects on a consolidated basis include, but are not limited to: changes in economic conditions, legislative/regulatory changes, availability of capital, interest rates, competition, and generally accepted accounting principles. These risks and uncertainties should also be considered in evaluating forward-looking statements and undue reliance should not be placed on such statements. We undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise. Further information concerning our business, including additional factors that could materially affect our financial results, is included herein and in our other filings with the SEC.

Overview

Company Highlights through July, 2018

	1)	Our net revenue for the first six months of 2018 was $9.2 million, up 84% over the same period in 2017. The increase is attributable to financial and brand messaging growth from new and returning clients.
	2)	Our net revenue for the second quarter of 2018 was $5.1 million, an increase of 78% versus the same quarter in 2017.
	3)	We completed a 1 for 3 reverse stock split in May 2018, and up-listed our stock to the Nasdaq Capital Markets in June 2018.
	4)	We raised $9.0 million in a private placement of common stock with two established institutional investors, which solidified our balance sheet and provided capital to further grow our business.
	5)	We expanded our board of directors, adding two new independent directors, Patrick Spangler and Bryan Archambault, as well as established an audit committee to further improve our corporate governance.
	6)	We continued to focus on adding additional brands for existing clients, providing new solutions, expanding the utilization of our network for existing brands, and obtaining new pharmaceutical manufacturer clients and advertising agencies.

Our success in acquiring, integrating and expanding into new electronic health record (EHR) and electronic prescribing (eRx) platforms continues to grow. For the remainder of 2018, we expect to expand our reach to physicians, pharmacies and patients, and also increase the utilization of our existing partners as they improve their work flow and reach. With the growth of both our pharmaceutical products and our distribution network, we expect that our financial, brand, and clinical messaging will continue to increase and show strong growth throughout the year.

Results of Operations for the Three and Six Months Ended June 30, 2018 and 2017

Revenues

Our total net revenue for the three months ended June 30, 2018 was approximately $5.1 million, an increase of 78% over the approximately $2.9 million from the same period in 2017. Our total net revenue for the six months ended June 30, 2018 was approximately $9.2 million, an increase of 84% over the approximately $5.0 million from the same period in 2017. The increase in both periods was due primarily to increases in our brand messaging products, as well as expanded distribution channels for our financial messaging. Additionally, the launch of new pharmaceutical brands, which total over 100 between financial and brand messaging, also contributed to the increase.

We do not breakout revenue by service at this stage, but as we achieve greater scale we plan to determine the best way to present the growth by service. As described in greater detail in Note 2 to the financial statements, we adopted the new revenue standard during the quarter ended March 31, 2018. The effect of that, which was immaterial, was to decrease our revenue by approximately $26,000 during the quarter and by approximately $142,000 for the six-month period. Virtually all of that revenue, however, will be recognized throughout the remainder of 2018.

Cost of Revenues

Our cost of revenues, comprised primarily of revenue share expense, increased in the three and six months ended June 30, 2018 over the same periods in 2017 as a result of the revenue increases. However, as a percentage of revenues, cost of revenues decreased in 2018 over 2017 as reflected in the table below. This decrease in our cost of revenue percentages is primarily the result of our focus on reducing revenue share percentages on our financial messaging and the launch of our brand messaging in 2017. During the launch period in 2017, we had only nominal margins on these products, but by 2018 we had achieved greater scale on these products, resulting in normal margin and an overall increase in margin.

	Three months ended June 30						Six months ended June 30
	2018			2017			2018			2017

Cost of Revenues %		43.9	%		56.0	%		46.0	%		59.5	%
Gross Margin %		56.1	%		44.0	%		54.0	%		40.5	%

Gross Margin

Our gross margins improved from 2017 to 2018 in both the three and six month periods ended June 30 for the similar reasons mentioned in the discussion of cost of revenues above. We have been focused on improving our margins and were targeting a gross margin of at least 55% by the fourth quarter of 2018. We achieved that goal ahead of schedule in the recently completed second quarter and are now focused on maintaining, or improving, those margins. Our overall margin is impacted by product mix, so there may be variations in margin from quarter to quarter, depending on the product mix, introduction of new products, and other factors.

Operating Expenses

Operating expenses increased from approximately $1.6 million for the three months ended June 30, 2017 to approximately $2.6 million for the same period in 2018. Operating expenses increased from approximately $3.3 million for the six months ended June 30, 2017 to approximately $4.9 million for the same period in 2018. The detail by major category is reflected in the table below.

	Three Months Ended June 30,				Six Months Ended June 30,
	2018		2017		2018		2017

Salaries, Wages, & Benefits	$	1,306,689	$	882,646	$	2,516,986	$	1,615,674
Stock-based compensation		516,700		162,431		1,013,822		291,875
Professional Fees		116,373		51,448		179,399		183,663
Board Compensation		33,375		18,750		58,625		37,500
Investor Relations		26,628		22,758		52,865		52,143
Consultants		29,809		100,661		39,809		208,721
Advertising and Promotion		97,977		37,177		118,728		144,240
Depreciation and Amortization		54,473		70,973		108,945		141,945
Development and Maintenance		119,372		88,267		325,312		183,263
Integration Incentives		40,626		61,500		81,252		162,342
Office, Facility, and other		154,165		71,745		226,972		135,921
Travel and Entertainment		92,939		62,497		161,752		134,344

Total Operating Expense	$	2,589,126	$	1,630,853	$	4,884,467	$	3,291,631

The largest increases in operating expenses related to salaries, wages, and benefits and other human resource-related costs. Since the beginning of the first quarter of 2017, we have appointed a new president, a new VP of engineering and two new vice presidents of sales, as well as hired a new account manager and related technical and administrative support. These new team members also resulted in increases in benefits, payroll taxes, travel, and stock compensation. We also implemented new incentive compensation plans for our sales force that increased their incentive compensation. In addition, virtually all of our incentive compensation is tied to revenue and the strong revenue growth in 2018 resulted in increased incentive compensation. The increased stock-based compensation results from the acceleration of vesting of previously granted options as well as the grant of options during the period related to achievement of performance-based goals. The expense related to stock compensation is also correlated to our stock price and the increase in our stock price results in an increase in stock compensation expense. We expect stock-based compensation to remain at similar levels on a quarterly basis for the balance of the year.

As reflected in the table below, our operating expenses decreased as a percentage of overall revenue.

	Three months ended June 30						Six months ended June 30
	2018			2017			2018			2017
Operating expense as a percentage of revenue, excluding litigation settlements		50.1	%		56.9	%		53.0	%		65.6	%

We expect our overall operating expenses to continue to increase slightly on a quarter to quarter basis as we further implement our business plan and expand our operations to grow the business in a very dynamic and active marketplace; however, we expect operating expense as a percentage of revenue to continue to decrease.

Net Income (Loss)

We had net income of approximately $280,000 for the three months ended June 30, 2018 as compared to a loss of approximately $362,000 during the same period in 2017. Our net income for the six months ended June 30, 2018 was approximately $91,000, as compared to a loss of approximately $1.2 million during the same period in 2017. The reasons for specific components are discussed above, however our increased revenues have resulted in us achieving profitability. We expect to continue to be profitable on a quarterly basis, although in any particular quarter, one-time expenses related to growth initiatives could result in a loss for a particular quarter.

Liquidity and Capital Resources

As of June 30, 2018, we had total current assets of approximately $17.7 million, compared with current liabilities of approximately $2.8 million, resulting in working capital of approximately $14.9 million and a current ratio of approximately 6.2 to 1. This was an improvement from working capital of approximately $5.3 million and a current ratio of 2.5 to 1 at December 31, 2017.

Our operating activities used approximately $1.2 million in cash during the six months ended June 30, 2018, compared to approximately $700,000 in the same period in 2017. The cash used in the 2017 period was the result of our net loss, partially offset by working capital management. The cash used in the 2018 period was primarily the result of our significant increase in revenues, resulting in a significantly larger amount of accounts receivable. We also had a change in payment terms for one of our key partners, which resulted in a reduction of our revenue share payable, as well as payment of certain year-end liabilities that occurred in 2018. We expect to have positive cash flow from operations on a quarterly basis for the balance of the year.

We used insignificant amounts in investing activities in the six months ended June 30, 2018, and 2017. These investments related to purchases of equipment as well as investments related to the expansion of our network capabilities.

We had cash provided from financing activities of approximately $8.2 million during the six months ended June 30, 2018, compared with cash used of $390,000 in the same period in 2017. During that period, we issued 1.667 million shares of our common stock for gross proceeds of $9.0 million and approximate net proceeds of $8.2 million. In addition, as discussed in Note 3, we issued 100,000 shares valued at $447,000 in a non-cash transaction in payment of revenue share due under a comarketing agreement and the accompanying termination of the agreement. We used cash in financing activities in the same period in 2017 for the repurchase of shares held by our previous CEO.

With the additional capital that we raised this year, we do not anticipate the need to raise additional capital in the short or long term for operating purposes or to fund our growth plans. We are focused on growing our revenue, channel and partner network. However, as a company in a market that is active with merger and acquisition activities, we may have opportunities, such as for acquisitions or strategic partner relationships, which may require additional capital. We will assess these opportunities as they arise with the view of maximizing shareholder value.

Off Balance Sheet Arrangements

As of June 30, 2018, there were no off-balance sheet arrangements.

Critical Accounting Policies

In December 2001, the SEC requested that all registrants list their most “critical accounting polices” in the Management Discussion and Analysis. The SEC indicated that a “critical accounting policy” is one which is both important to the portrayal of a company’s financial condition and results, and requires management’s most difficult, subjective or complex judgments, often as a result of the need to make estimates about the effect of matters that are inherently uncertain. Our accounting policies are discussed in the footnotes to our financial statements included in our annual report on Form 10-K for the year ended December 31, 2017; however, we consider our critical accounting policies to be those related to the amount of revenue to be billed, the timing of revenue recognition, calculation of revenue share expense, stock-based compensation, capitalization and related amortization of intangible assets, and impairment of assets.

Recently Issued Accounting Pronouncements

As described in greater detail in Note 2, we adopted the new accounting standard ASC 606, Revenue from Contracts with Customers, and all of the related amendments, which had an immaterial impact on our financial statements.

In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842) (“ASU 2016-02”), which modifies lease accounting for lessees to increase transparency and comparability by recording lease assets and liabilities for operating leases and disclosing key information about leasing arrangements. The Company will adopt ASU 2016-02 in its first quarter of 2019. While the Company is currently evaluating the timing and impact of adopting ASU 2016-02, currently the Company anticipates no material impact to its Consolidated Statements of Operations. However, the ultimate impact of adopting ASU 2016-02 will depend on the Company’s lease portfolio as of the adoption date.

Item 3. Quantitative and Qualitative Disclosures about Market Risk

A smaller reporting company is not required to provide the information required by this Item.

Item 4. Controls and Procedures

Disclosure Controls and Procedures

Under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer, we conducted an evaluation of the effectiveness of the design and operation of our disclosure controls and procedures, as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934 (the “Exchange Act”), as of the end of the period covered by this report (the “Evaluation Date”). Based upon this evaluation, our Chief Executive Officer and Chief Financial Officer concluded as of the Evaluation Date that our disclosure controls and procedures were effective such that the material information required to be included in our SEC reports is recorded, processed, summarized, and reported within the time periods specified in SEC rules and forms relating to the our company, including, our consolidated subsidiary, and was made known to them by others within those entities, particularly during the period when this report was being prepared.

Changes in Internal Control over Financial Reporting

There were no changes in our internal control over financial reporting during the six months ended June 30, 2018 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

Limitations on the Effectiveness of Controls

Our management, including our Chief Executive Officer and Chief Financial Officer, does not expect that our disclosure controls and procedures or our internal controls will prevent all error and all fraud. A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Further, the design of a control system must reflect the fact that there are resource constraints and the benefits of controls must be considered relative to their costs. Due to the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within our company have been detected.

PART II – OTHER INFORMATION

Item 1. Legal Proceedings

We are not a party to any material pending legal proceeding. We are not aware of any pending legal proceeding to which any of our officers, directors, or any beneficial holders of 5% or more of our voting securities are adverse to us or have a material interest adverse to us.

Item 1A: Risk Factors

See risk factors included in the Company’s Annual Report on Form 10-K for 2017.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

We issued 6,252 and 8,336 shares of common stock in March 2018 and June 2018, respectively, to our independent directors in connection with our Director Compensation Plan.

In May 2018, we issued an aggregate of 1,666,669 shares of our common stock, par value $0.001 per share for $5.40 per share, or gross proceeds of $9,000,000. The net proceeds of the offering of approximately $8.2 million will be used for working capital purposes.

These securities were issued pursuant to Section 4(2) of the Securities Act and/or Rule 506 promulgated thereunder. The holders represented their intention to acquire the securities for investment only and not with a view towards distribution. The investors were given adequate information about us to make an informed investment decision. We did not engage in any general solicitation or advertising. We directed our transfer agent to issue the stock certificates with the appropriate restrictive legend affixed to the restricted stock.

Item 3. Defaults upon Senior Securities

None

Item 4. Mine Safety Disclosure

N/A

Item 5. Other Information

None

Item 6. Exhibits

Exhibit Number		Description of Exhibit
31.1		Certification of Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
31.2		Certification of Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
32.1		Certification of Chief Executive Officer and Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
101**		The following materials from the Company’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2018 formatted in Extensible Business Reporting Language (XBRL).

** Provided herewith

SIGNATURES

In accordance with the requirements of the Securities and Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

OptimizeRx Corporation

Date:	August 7, 2018

By:	/s/ Will Febbo
	Will Febbo
Title:	Chief Executive Officer, Principal Executive Officer, and Director

OptimizeRx Corporation

Date:	August 7, 2018

By:	/s/ Douglas P. Baker
	Douglas P. Baker
Title:	Chief Financial Officer, Principal Financial Officer and Principal Accounting Officer

Exhibit 31.1

CERTIFICATIONS

I, Will Febbo, certify that;

I have reviewed this quarterly report on Form 10-Q for the quarter ended June 30, 2018 of OptimizeRx Corp (the “registrant”);

Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: August 7, 2018

/s/ Will Febbo
By: Will Febbo
Title: Chief Executive Officer

Exhibit 31.2

CERTIFICATIONS

I, Douglas Baker, certify that;

I have reviewed this quarterly report on Form 10-Q for the quarter ended June 30, 2018 of OptimizeRx Corp (the “registrant”);

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: August 7, 2018

/s/ Douglas Baker
By: Douglas Baker
Title: Chief Financial Officer

Exhibit 32.1

CERTIFICATION OF CHIEF EXECUTIVE OFFICER AND

CHIEF FINANCIAL OFFICER

PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the quarterly Report of OptimizeRx Corp (the “Company”) on Form 10-Q for the quarter ended June 30, 2018 filed with the Securities and Exchange Commission (the “Report”), I, Will Febbo, Chief Executive Officer and I, Douglas Baker, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

The Report fully complies with the requirements of Section 13(a) of the Securities Exchange Act of 1934; and

The information contained in the Report fairly presents, in all material respects, the consolidated financial condition of the Company as of the dates presented and the consolidated result of operations of the Company for the periods presented.

By:	/s/ Will Febbo
Name:	Will Febbo
Title:	Principal Executive Officer, and Director
Date:	August 7, 2018

By:	/s/ Douglas Baker
Name:	Douglas Baker
Title:	Principal Financial Officer
Date:	August 7, 2018

This certification has been furnished solely pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.